Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection.
Identifieur interne : 001217 ( PubMed/Corpus ); précédent : 001216; suivant : 001218Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection.
Auteurs : Oi-Wing Ng ; Adeline Chia ; Anthony T. Tan ; Ramesh S. Jadi ; Hoe Nam Leong ; Antonio Bertoletti ; Yee-Joo TanSource :
- Vaccine [ 1873-2518 ] ; 2016.
English descriptors
- KwdEn :
- CD8-Positive T-Lymphocytes (immunology), Cross Reactions, Epitopes, T-Lymphocyte (immunology), Histocompatibility Antigens Class I (immunology), Humans, Immunity, Cellular, Immunologic Memory, Middle East Respiratory Syndrome Coronavirus, Nucleocapsid Proteins (immunology), SARS Virus, Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Viral Matrix Proteins (immunology).
- MESH :
- chemical , immunology : Epitopes, T-Lymphocyte, Histocompatibility Antigens Class I, Nucleocapsid Proteins, Viral Matrix Proteins.
- immunology : CD8-Positive T-Lymphocytes, Severe Acute Respiratory Syndrome.
- prevention & control : Severe Acute Respiratory Syndrome.
- Cross Reactions, Humans, Immunity, Cellular, Immunologic Memory, Middle East Respiratory Syndrome Coronavirus, SARS Virus.
Abstract
Severe acute respiratory syndrome (SARS) is a highly contagious infectious disease which first emerged in late 2002, caused by a then novel human coronavirus, SARS coronavirus (SARS-CoV). The virus is believed to have originated from bats and transmitted to human through intermediate animals such as civet cats. The re-emergence of SARS-CoV remains a valid concern due to the continual persistence of zoonotic SARS-CoVs and SARS-like CoVs (SL-CoVs) in bat reservoirs. In this study, the screening for the presence of SARS-specific T cells in a cohort of three SARS-recovered individuals at 9 and 11 years post-infection was carried out, and all memory T cell responses detected target the SARS-CoV structural proteins. Two CD8(+) T cell responses targeting the SARS-CoV membrane (M) and nucleocapsid (N) proteins were characterized by determining their HLA restriction and minimal T cell epitope regions. Furthermore, these responses were found to persist up to 11 years post-infection. An absence of cross-reactivity of these CD8(+) T cell responses against the newly-emerged Middle East respiratory syndrome coronavirus (MERS-CoV) was also demonstrated. The knowledge of the persistence of SARS-specific celullar immunity targeting the viral structural proteins in SARS-recovered individuals is important in the design and development of SARS vaccines, which are currently unavailable.
DOI: 10.1016/j.vaccine.2016.02.063
PubMed: 26954467
Links to Exploration step
pubmed:26954467Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection.</title><author><name sortKey="Ng, Oi Wing" sort="Ng, Oi Wing" uniqKey="Ng O" first="Oi-Wing" last="Ng">Oi-Wing Ng</name><affiliation><nlm:affiliation>Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University Health System (NUHS), National University of Singapore, Singapore.</nlm:affiliation></affiliation></author><author><name sortKey="Chia, Adeline" sort="Chia, Adeline" uniqKey="Chia A" first="Adeline" last="Chia">Adeline Chia</name><affiliation><nlm:affiliation>Program Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore.</nlm:affiliation></affiliation></author><author><name sortKey="Tan, Anthony T" sort="Tan, Anthony T" uniqKey="Tan A" first="Anthony T" last="Tan">Anthony T. Tan</name><affiliation><nlm:affiliation>Program Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore.</nlm:affiliation></affiliation></author><author><name sortKey="Jadi, Ramesh S" sort="Jadi, Ramesh S" uniqKey="Jadi R" first="Ramesh S" last="Jadi">Ramesh S. Jadi</name><affiliation><nlm:affiliation>Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University Health System (NUHS), National University of Singapore, Singapore.</nlm:affiliation></affiliation></author><author><name sortKey="Leong, Hoe Nam" sort="Leong, Hoe Nam" uniqKey="Leong H" first="Hoe Nam" last="Leong">Hoe Nam Leong</name><affiliation><nlm:affiliation>Singapore General Hospital, Singapore.</nlm:affiliation></affiliation></author><author><name sortKey="Bertoletti, Antonio" sort="Bertoletti, Antonio" uniqKey="Bertoletti A" first="Antonio" last="Bertoletti">Antonio Bertoletti</name><affiliation><nlm:affiliation>Program Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore; Viral Hepatitis Laboratory, Singapore Institute for Clinical Sciences, Agency of Science Technology and Research (A*STAR), Singapore.</nlm:affiliation></affiliation></author><author><name sortKey="Tan, Yee Joo" sort="Tan, Yee Joo" uniqKey="Tan Y" first="Yee-Joo" last="Tan">Yee-Joo Tan</name><affiliation><nlm:affiliation>Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University Health System (NUHS), National University of Singapore, Singapore; Institute of Molecular and Cell Biology, A*STAR (Agency for Science, Technology and Research), Singapore. Electronic address: Yee_Joo_TAN@NUHS.edu.sg.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26954467</idno><idno type="pmid">26954467</idno><idno type="doi">10.1016/j.vaccine.2016.02.063</idno><idno type="wicri:Area/PubMed/Corpus">001217</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001217</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection.</title><author><name sortKey="Ng, Oi Wing" sort="Ng, Oi Wing" uniqKey="Ng O" first="Oi-Wing" last="Ng">Oi-Wing Ng</name><affiliation><nlm:affiliation>Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University Health System (NUHS), National University of Singapore, Singapore.</nlm:affiliation></affiliation></author><author><name sortKey="Chia, Adeline" sort="Chia, Adeline" uniqKey="Chia A" first="Adeline" last="Chia">Adeline Chia</name><affiliation><nlm:affiliation>Program Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore.</nlm:affiliation></affiliation></author><author><name sortKey="Tan, Anthony T" sort="Tan, Anthony T" uniqKey="Tan A" first="Anthony T" last="Tan">Anthony T. Tan</name><affiliation><nlm:affiliation>Program Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore.</nlm:affiliation></affiliation></author><author><name sortKey="Jadi, Ramesh S" sort="Jadi, Ramesh S" uniqKey="Jadi R" first="Ramesh S" last="Jadi">Ramesh S. Jadi</name><affiliation><nlm:affiliation>Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University Health System (NUHS), National University of Singapore, Singapore.</nlm:affiliation></affiliation></author><author><name sortKey="Leong, Hoe Nam" sort="Leong, Hoe Nam" uniqKey="Leong H" first="Hoe Nam" last="Leong">Hoe Nam Leong</name><affiliation><nlm:affiliation>Singapore General Hospital, Singapore.</nlm:affiliation></affiliation></author><author><name sortKey="Bertoletti, Antonio" sort="Bertoletti, Antonio" uniqKey="Bertoletti A" first="Antonio" last="Bertoletti">Antonio Bertoletti</name><affiliation><nlm:affiliation>Program Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore; Viral Hepatitis Laboratory, Singapore Institute for Clinical Sciences, Agency of Science Technology and Research (A*STAR), Singapore.</nlm:affiliation></affiliation></author><author><name sortKey="Tan, Yee Joo" sort="Tan, Yee Joo" uniqKey="Tan Y" first="Yee-Joo" last="Tan">Yee-Joo Tan</name><affiliation><nlm:affiliation>Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University Health System (NUHS), National University of Singapore, Singapore; Institute of Molecular and Cell Biology, A*STAR (Agency for Science, Technology and Research), Singapore. Electronic address: Yee_Joo_TAN@NUHS.edu.sg.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>CD8-Positive T-Lymphocytes (immunology)</term><term>Cross Reactions</term><term>Epitopes, T-Lymphocyte (immunology)</term><term>Histocompatibility Antigens Class I (immunology)</term><term>Humans</term><term>Immunity, Cellular</term><term>Immunologic Memory</term><term>Middle East Respiratory Syndrome Coronavirus</term><term>Nucleocapsid Proteins (immunology)</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Viral Matrix Proteins (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Epitopes, T-Lymphocyte</term><term>Histocompatibility Antigens Class I</term><term>Nucleocapsid Proteins</term><term>Viral Matrix Proteins</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>CD8-Positive T-Lymphocytes</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cross Reactions</term><term>Humans</term><term>Immunity, Cellular</term><term>Immunologic Memory</term><term>Middle East Respiratory Syndrome Coronavirus</term><term>SARS Virus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a highly contagious infectious disease which first emerged in late 2002, caused by a then novel human coronavirus, SARS coronavirus (SARS-CoV). The virus is believed to have originated from bats and transmitted to human through intermediate animals such as civet cats. The re-emergence of SARS-CoV remains a valid concern due to the continual persistence of zoonotic SARS-CoVs and SARS-like CoVs (SL-CoVs) in bat reservoirs. In this study, the screening for the presence of SARS-specific T cells in a cohort of three SARS-recovered individuals at 9 and 11 years post-infection was carried out, and all memory T cell responses detected target the SARS-CoV structural proteins. Two CD8(+) T cell responses targeting the SARS-CoV membrane (M) and nucleocapsid (N) proteins were characterized by determining their HLA restriction and minimal T cell epitope regions. Furthermore, these responses were found to persist up to 11 years post-infection. An absence of cross-reactivity of these CD8(+) T cell responses against the newly-emerged Middle East respiratory syndrome coronavirus (MERS-CoV) was also demonstrated. The knowledge of the persistence of SARS-specific celullar immunity targeting the viral structural proteins in SARS-recovered individuals is important in the design and development of SARS vaccines, which are currently unavailable.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26954467</PMID><DateCompleted><Year>2016</Year><Month>10</Month><Day>12</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>17</Issue><PubDate><Year>2016</Year><Month>Apr</Month><Day>12</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection.</ArticleTitle><Pagination><MedlinePgn>2008-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2016.02.063</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(16)00258-9</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome (SARS) is a highly contagious infectious disease which first emerged in late 2002, caused by a then novel human coronavirus, SARS coronavirus (SARS-CoV). The virus is believed to have originated from bats and transmitted to human through intermediate animals such as civet cats. The re-emergence of SARS-CoV remains a valid concern due to the continual persistence of zoonotic SARS-CoVs and SARS-like CoVs (SL-CoVs) in bat reservoirs. In this study, the screening for the presence of SARS-specific T cells in a cohort of three SARS-recovered individuals at 9 and 11 years post-infection was carried out, and all memory T cell responses detected target the SARS-CoV structural proteins. Two CD8(+) T cell responses targeting the SARS-CoV membrane (M) and nucleocapsid (N) proteins were characterized by determining their HLA restriction and minimal T cell epitope regions. Furthermore, these responses were found to persist up to 11 years post-infection. An absence of cross-reactivity of these CD8(+) T cell responses against the newly-emerged Middle East respiratory syndrome coronavirus (MERS-CoV) was also demonstrated. The knowledge of the persistence of SARS-specific celullar immunity targeting the viral structural proteins in SARS-recovered individuals is important in the design and development of SARS vaccines, which are currently unavailable.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Oi-Wing</ForeName><Initials>OW</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University Health System (NUHS), National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chia</LastName><ForeName>Adeline</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Program Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Anthony T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Program Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jadi</LastName><ForeName>Ramesh S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University Health System (NUHS), National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leong</LastName><ForeName>Hoe Nam</ForeName><Initials>HN</Initials><AffiliationInfo><Affiliation>Singapore General Hospital, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertoletti</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Program Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore; Viral Hepatitis Laboratory, Singapore Institute for Clinical Sciences, Agency of Science Technology and Research (A*STAR), Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Yee-Joo</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University Health System (NUHS), National University of Singapore, Singapore; Institute of Molecular and Cell Biology, A*STAR (Agency for Science, Technology and Research), Singapore. Electronic address: Yee_Joo_TAN@NUHS.edu.sg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019590">Nucleocapsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014763">Viral Matrix Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C099602">nucleocapsid protein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>108502-71-2</RegistryNumber><NameOfSubstance UI="C067997">M protein, Coronavirus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015395" MajorTopicYN="N">Histocompatibility Antigens Class I</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="Y">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007156" MajorTopicYN="Y">Immunologic Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019590" MajorTopicYN="N">Nucleocapsid Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014763" MajorTopicYN="N">Viral Matrix Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Epitope</Keyword><Keyword MajorTopicYN="N">Immunity</Keyword><Keyword MajorTopicYN="N">SARS-CoV</Keyword><Keyword MajorTopicYN="N">T cell</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>09</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>02</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>02</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26954467</ArticleId><ArticleId IdType="pii">S0264-410X(16)00258-9</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2016.02.063</ArticleId><ArticleId IdType="pmc">PMC7115611</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Virol. 2010 Sep;84(18):9318-25</Citation><ArticleIdList><ArticleId IdType="pubmed">20610717</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Microbiol Rev. 2007 Oct;20(4):660-94</Citation><ArticleIdList><ArticleId IdType="pubmed">17934078</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Immunol. 2006 Aug;120(2):171-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16781892</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Arch Virol. 2009;154(7):1093-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19526193</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2013 Nov 28;503(7477):535-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24172901</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2006 May 26;344(1):63-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16630549</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>mBio. 2012 Nov 20;3(6):</Citation><ArticleIdList><ArticleId IdType="pubmed">23170002</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16169905</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2006 Aug 15;177(4):2138-45</Citation><ArticleIdList><ArticleId IdType="pubmed">16887973</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2013 Oct 15;191(8):4010-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24058176</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Microbiol Rev. 2015 Apr;28(2):465-522</Citation><ArticleIdList><ArticleId IdType="pubmed">25810418</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2013 Jul;87(14):7790-2</Citation><ArticleIdList><ArticleId IdType="pubmed">23678167</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Cell Biol. 1993 Aug;5(4):596-605</Citation><ArticleIdList><ArticleId IdType="pubmed">8257600</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2010 Oct 15;202(8):1171-80</Citation><ArticleIdList><ArticleId IdType="pubmed">20831383</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2011 Oct;85(20):10464-71</Citation><ArticleIdList><ArticleId IdType="pubmed">21813600</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2004 Feb 15;189(4):648-51</Citation><ArticleIdList><ArticleId IdType="pubmed">14767818</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 2008 Apr;133(1):13-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17374415</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol Methods. 2003 Oct 1;281(1-2):65-78</Citation><ArticleIdList><ArticleId IdType="pubmed">14580882</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2014 Oct;88(19):11034-44</Citation><ArticleIdList><ArticleId IdType="pubmed">25056892</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 May;78(9):4638-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15078946</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2008 Oct 15;181(8):5490-500</Citation><ArticleIdList><ArticleId IdType="pubmed">18832706</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2010 Feb;84(3):1289-301</Citation><ArticleIdList><ArticleId IdType="pubmed">19906920</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2004 Dec;10(12 Suppl):S88-97</Citation><ArticleIdList><ArticleId IdType="pubmed">15577937</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2006 Dec 20;1:e24</Citation><ArticleIdList><ArticleId IdType="pubmed">17183651</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2005 Oct 28;310(5748):676-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16195424</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2008 Nov 25;26(50):6338-43</Citation><ArticleIdList><ArticleId IdType="pubmed">18824060</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001217 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001217 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26954467
|texte= Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26954467" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |